EGFR inhibitors (in colorectal cancer)

GPTKB entity

Predicate	Object
gptkbp:instanceOf	targeted therapy
gptkbp:approvedBy	gptkb:FDA cetuximab in 2004
gptkbp:biomarkerRequired	wild-type RAS
gptkbp:clinicalTrialPhase	phase III
gptkbp:combines	chemotherapy
gptkbp:contraindication	history of severe hypersensitivity to monoclonal antibodies
gptkbp:guidelineRecommendation	gptkb:NCCN_guidelines
https://www.w3.org/2000/01/rdf-schema#label	EGFR inhibitors (in colorectal cancer)
gptkbp:lessEffectiveIn	right-sided colorectal cancer
gptkbp:mechanismOfAction	block EGFR signaling pathway
gptkbp:notEffectiveAgainst	gptkb:KRAS-mutant_colorectal_cancer
gptkbp:notRecommendedFor	gptkb:BRAF_V600E-mutant_colorectal_cancer
gptkbp:resistantTo	gptkb:KRAS_mutation BRAF mutation EGFR extracellular domain mutation HER2 amplification MET amplification NRAS mutation
gptkbp:routeOfAdministration	intravenous
gptkbp:sideEffect	diarrhea skin rash hypomagnesemia
gptkbp:target	gptkb:cetuximab gptkb:nimotuzumab gptkb:zalutumumab gptkb:epidermal_growth_factor_receptor_(EGFR) gptkb:panitumumab
gptkbp:usedFor	metastatic colorectal cancer
gptkbp:usedIn	left-sided colorectal cancer
gptkbp:bfsParent	gptkb:BRAF_V600E
gptkbp:bfsLayer	6